OmniAb (OABI) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 163.2% versus a loss of 35.5%. Over five years, OABI leads with a -53.3% price change compared with -78.1% for PHAT. OmniAb is the larger company by market cap ($696.4 million vs $586.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OABI | PHAT |
|---|---|---|
| Share price | $4.79 | $7.25 |
| Market cap | $696.42M | $586.53M |
| 1-day change | +2.79% | +1.68% |
| YTD return | +158.92% | -57.02% |
| 1-year return | +163.19% | -35.48% |
| 5-year return | -53.26% | -78.07% |
| Forward P/E | — | 6.73 |
| EPS (TTM) | $-0.36 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.43 | $18.31 |
| 52-week low | $1.30 | $6.52 |
| Distance from 52-week high | -11.79% | -60.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +73.90% | +182.07% |
| Average volume | 1.47M | 1.38M |
| Shares outstanding | 145.39M | 80.90M |
| Employees | 89 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed PHAT by 198.7 percentage points over the past year.
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
OABI vs PHAT FAQ
Which is bigger, OmniAb or Phathom Pharmaceuticals?
OmniAb (OABI) is larger, with a market capitalization of $696.42M compared with $586.53M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, OABI or PHAT?
OABI returned +163.19% over the past 12 months, compared with -35.48% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are OmniAb and Phathom Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for OmniAb and Biotechnology: Pharmaceutical Preparations for Phathom Pharmaceuticals.